The first tubeless, waterproof AID system is approved in Canada for people with type 1 diabetes ages two years and above. In Canada, it pairs with the Dexcom G6 and G7 continuous glucose monitor (CGM) systems to automatically deliver insulin.
Currently, Ontario and Nova Scotia have public reimbursement in place for Omnipod 5 in Canada. Insulet intends to expand coverage across additional provinces and territories throughout the country.
Omnipod 5 is the company’s latest-generation insulin delivery system. A small, discreet, tubeless, wearable patch pump, Omnipod 5 features SmartAdjust technology that uses CGM readings to predict where glucose will be 60 minutes into the future. It then increases, decreases, or pauses insulin delivery based on the user’s desired and customized glucose target.
This launch comes as part of a widespread rollout in several different geographies announced last month. The company made Omnipod 5 available in Australia and outlined planned launches for Belgium, Canada and Switzerland down the line. This follows the launch of Omnipod 5 in five new European countries at the start of this year.
“We are thrilled to bring our flagship Omnipod 5 AID system to Canadians,” said Janet James, GM, Insulet Canada. “This marks a significant step forward to help improve the lives of people living with type 1 diabetes. We have seen first-hand the health and lifestyle benefits Omnipod 5 provides to our users in other countries and are eager to see timely access provided for all Canadians with type 1 diabetes through their provincial health plans.”
